Statistical analysis that was performed for IL-1β, taking into account the status of Her2-neu, ER and PR, all combined (currently each of these three factors is used in the clinic as predictors of disease progression and recurrence in breast cancer), indicated that IL-1β was a significant risk factor for disease relapse: p = 0.0402, with 95% confidence limits of 1.098 and 59.93 and odds ratio 1 value of 8.112 (also, of the different clinical markers, PR was statistically different between the IDC-no-relapse and IDC-with-relapse groups, with p = 0.0391). Here, ESR1 is linked to breast carcinoma.